What question did this study set out to answer?

This research aims to assess the effectiveness and safety of bariatric surgery in Asians with severe obesity (BMI ≥ 50 kg/m2).

April 30, 2026Journal of Clinical Medicine0 citationsOpen Access

View Full Paper

Bariatric Surgery Outcomes in Asians with Severe Obesity (BMI ≥ 50 Kg/m2)

STSarah Ying Tse Tan TLTrilene Ruiting Liang JCJasmine Kai Ling Chua

Key Points

This research aims to assess the effectiveness and safety of bariatric surgery in Asians with severe obesity (BMI ≥ 50 kg/m2).
Participants with BMI ≥ 50 kg/m2 were recruited for metabolic bariatric surgery from 2008 to 2022.
Data on demographics, biochemistry, and diabetes status were collected at baseline and 12 and 24 months post-operative.
Surgical outcomes, complications, and weight loss were analyzed comparing gastric bypass and sleeve gastrectomy.
184 participants included, with majorities undergoing sleeve gastrectomy.
Average total weight loss was comparable between groups at 12 and 24 months.
Diabetes remission rates did not differ significantly, though HbA1c reduction was greater in the gastric bypass group.

Abstract

Background: The benefits of metabolic bariatric surgery (MBS) in people with a body mass index (BMI) ≥ 50 kg/m2 are not well-established, with concerns of increased risk and poorer weight loss. The optimal surgical type (gastric bypass GB versus sleeve gastrectomy SG) is unclear, with studies comparing complication rates, weight loss, and glycaemic outcomes reporting mixed results. Methods: Participants with a BMI ≥ 50 kg/m2 undergoing MBS (SG or GB) from 2008 to 2022 were recruited. Demographics, anthropometrics, biochemistry, and diabetes status were analysed at baseline, 12 months, and 24 months post-operatively. Surgical outcomes and complications were analysed. Results: The study included n = 184, with BMI ≥ 50 kg/m2 (57.6% female, age 38.6 ± 10.5 years, and BMI 55.3 ± 6.0 kg/m2). Pre-operatively, 21.1% had pre-diabetes, and 33.2% had diabetes (mean HbA1c 8.0 ± 1.7%). Most subjects (89.1%) underwent SG. The overall 30-day adverse event rate was 4.9%, with a higher, but not statistically significant, rate in the GB group (15.0% vs 3.7%, p = 0.061). The GB group had a longer length of stay (GB =4.5 ± 0.6 days, SG = 3.1 ± 0.2, and p = 0.023). The rate of revisional surgery was 2.7%, with no significant difference between groups. The follow-up rate was 67.9% at 12 months and 51.1% at 24 months. The average %total weight loss (%TWL) at 12 months (27.4 ± 9.0%, SG = 27.6 ± 9.0%, GB = 26.0 ± 9.4%, and p = 0.481) and 24 months (27.1 ± 10.9%, SG = 27.4 ± 11.1%, GB = 24.9 ± 8.9%, and p = 0.495) were similar between groups. The GB group had a larger HbA1c reduction (3.2 ± 1.1%) than SG (1.9 ±1.3%, p = 0.030) but no difference in diabetes remission rates (69.2% at 12 months, 76.7% at 24 months). Conclusions: MBS is safe and effective for individuals with a BMI ≥ 50 kg/m2, with low complication rates and good weight loss and glycaemic outcomes at 2 years. No statistically significant differences in %TWL, diabetes remission, or complication rates were noted between SG and GB groups, though results are limited by the small number of participants who underwent GB.

AI에게 질문

Bookmark

View Full Paper

Cite This Study

Tan et al. (Sun,) studied this question.

synapsesocial.com/papers/69f2a4f18c0f03fd677641b6 https://doi.org/https://doi.org/10.3390/jcm15093305

AI에게 질문

Bookmark

View Full Paper